Skip to content

Insider · CIK 0001562371

Richard Barry

directorceopresidentofficer

Files at SRPT (Sarepta Therapeutics, Inc.), FLNA (CASSAVA SCIENCES INC). First filing Sep 22, 2025, latest Oct 1, 2026.

Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
6 / 0
$1.5M bought, $0 sold

Where the trades landed

Last year at the company this insider has traded most, with each buy and sell on the bar it happened.

FLNA: CASSAVA SCIENCES INC

FLNAOct 9, 2026 · close 0.82

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

This insider’s open-market buys and sells, scored.

ScoreCompanyValueHoldingsPrice contextFiled
58Moderate
FLNAbuy
CASSAVA SCIENCES INC
$278k
306,813 shares
+30%+35% from low-80% from high
45Moderate
FLNAbuy
CASSAVA SCIENCES INC
$78k
93,091 shares
+10%+25% from low-82% from high
65Notable
FLNAbuy 2
CASSAVA SCIENCES INC
$414k
150,000 shares
+19%+121% from low-92% from high
61Notable
FLNAbuy 2
CASSAVA SCIENCES INC
$202k
73,385 shares
+10%+131% from low-91% from high
46Moderate
FLNAbuy 2
CASSAVA SCIENCES INC
$16k
7,172 shares
+1%+95% from low-93% from high
69Notable
FLNAbuy 2
CASSAVA SCIENCES INC
$535k
237,941 shares
+51%+92% from low-93% from high

Transactions

Every row this insider has filed, newest first.

DateCompanyTransactionSharesPriceValueHoldings afterFiled
Sep 29, 2026FLNA
CASSAVA SCIENCES INC
POpen-market purchase
Common Stockindirect: By Trust
+206,813$0.90$186k1,237,96411 d ago
Sep 30, 2026FLNA
CASSAVA SCIENCES INC
POpen-market purchase
Common Stockindirect: By Trust
+100,000$0.92$92k1,337,96411 d ago
Sep 28, 2026FLNA
CASSAVA SCIENCES INC
POpen-market purchase
Common Stockindirect: By Trust
+93,091$0.84$78k1,031,15112 d ago
Nov 20, 2025FLNA
CASSAVA SCIENCES INC
POpen-market purchase
Common Stockindirect: By Trust
+150,000$2.76$414k938,060Nov 24, 2025
Nov 19, 2025FLNA
CASSAVA SCIENCES INC
POpen-market purchase
Common Stockindirect: By Trust
+73,385$2.75$202k788,060Nov 20, 2025
Sep 22, 2025FLNA
CASSAVA SCIENCES INC
POpen-market purchase
Common Stockindirect: By Trust
+7,172$2.28$16k714,675Sep 23, 2025
Sep 18, 2025FLNA
CASSAVA SCIENCES INC
POpen-market purchase
Common Stockindirect: By Trust
+5,400$2.13$12k474,962Sep 22, 2025
Sep 18, 2025FLNA
CASSAVA SCIENCES INC
POpen-market purchase
Common Stockindirect: By Trust
+185,233$2.24$415k660,195Sep 22, 2025
Sep 19, 2025FLNA
CASSAVA SCIENCES INC
POpen-market purchase
Common Stockindirect: By Trust
+400$2.25$900660,595Sep 22, 2025
Sep 19, 2025FLNA
CASSAVA SCIENCES INC
POpen-market purchase
Common Stockindirect: By Trust
+46,908$2.29$107k707,503Sep 22, 2025
May 16, 2025SRPT
Sarepta Therapeutics, Inc.
MOption exercise
Common Stock
+12,350$32.63$403k2,966,667May 19, 2025
May 16, 2025SRPT
Sarepta Therapeutics, Inc.
MOption exercise
Stock Option (right to buy)derivative
-12,350$0.00$00May 19, 2025
May 13, 2025SRPT
Sarepta Therapeutics, Inc.
MOption exercise
Common Stock
+9,746$25.18$245k2,943,817May 15, 2025
May 13, 2025SRPT
Sarepta Therapeutics, Inc.
MOption exercise
Common Stock
+10,500$13.71$144k2,954,317May 15, 2025
May 13, 2025SRPT
Sarepta Therapeutics, Inc.
MOption exercise
Stock Option (right to buy)derivative
-9,746$0.00$00May 15, 2025
May 13, 2025SRPT
Sarepta Therapeutics, Inc.
MOption exercise
Stock Option (right to buy)derivative
-10,500$0.00$00May 15, 2025
Apr 17, 2025FLNA
CASSAVA SCIENCES INC
AGrant or award
Stock Option (Right to Buy)derivative
+350,000$0.00$0350,000Apr 21, 2025
Mar 10, 2025SRPT
Sarepta Therapeutics, Inc.
AGrant or award
Common Stock
+2,383$0.00$02,934,071Mar 11, 2025
Mar 10, 2025SRPT
Sarepta Therapeutics, Inc.
AGrant or award
Stock Options (right to buy)derivative
+4,792$0.00$04,792Mar 11, 2025

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Richard Barry: insider trades and track record | InsiderTell